Clinical Trials Logo

Clinical Trial Summary

X-linked adrenoleukodystrophy is a rare, demyelinating and neurodegenerative disorder, due to a loss of function of a fatty acid transporter, the peroxisomal ABCD1protein. Its more frequent phenotype, the adrenomyeloneuropathy in adults, is characterized by axonal degeneration in spinal cord, spastic paraparesis and a disabling peripheral neuropathy. Actually, there is no efficient treatment for the disease. Our work in the last twelve years dissecting the physiopathological basis of the disorder has uncovered an involvement of the oxidative stress early in the neurodegenerative cascade. In a preclinical trial we have identified an antioxidant cocktail that efficiently reverse the clinical symptoms and the axonal degeneration in the mouse model for the disease. We propose the translation of the results to an open trial to test the tolerance and effectiveness of these drugs in the correction of the previously identified oxidative lesion biomarkers, as a first step to a randomized versus placebo, multicentric and international trial. You will be clinically explored and assessed in the Hospital Universitari of Bellvitge (HUB) using clinical scales for spasticity, disability, electroneurogram and cranial and spinal Nuclear Magnetic resonance (NMR). The information will be collected in a data base that will be of great value to improve the present attention and the future follow-up to facilitate your inclusion in therapeutic randomized, double blind, against placebo clinical trials.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT01495260
Study type Interventional
Source Onofre, Aurora Pujol, M.D.
Contact
Status Completed
Phase Phase 2
Start date September 2011
Completion date November 2013

See also
  Status Clinical Trial Phase
Not yet recruiting NCT05146284 - Study to Assess PXL770 in Subjects With Adrenomyeloneuropathy (AMN) Form of X-linked Adrenoleukodystrophy (X-ALD or ALD) Phase 2
Completed NCT02961803 - MD1003-AMN MD1003 in Adrenomyeloneuropathy Phase 2/Phase 3
Completed NCT04303416 - Plasma Exchange With Albumin in AMN Patients Phase 2/Phase 3
Terminated NCT00545597 - A Phase III Trial of Lorenzo's Oil in Adrenomyeloneuropathy Phase 3
Completed NCT01165060 - The Effect of Bezafibrate on the Level of Very Long Chain Fatty Acids (VLCFA) in X-linked Adrenoleukodystrophy (X-ALD) N/A
Completed NCT03627416 - Repetitive Transcranial Magnetic Stimulation as Therapy in Hereditary Spastic Paraplegia and Adrenomyeloneuropathy N/A
Active, not recruiting NCT02699190 - LeukoSEQ: Whole Genome Sequencing as a First-Line Diagnostic Tool for Leukodystrophies
Completed NCT03864523 - Effect of Pioglitazone Administered to Patients With Adrenomyeloneuropathy Phase 2
Recruiting NCT05443906 - Home Exercise for Individuals With Neurodegenerative Disease N/A
Recruiting NCT03047369 - The Myelin Disorders Biorepository Project
Recruiting NCT04925349 - Modeling Macrophages Activation Pattern in X-linked Adrenoleukodystrophy, Metachromatic Leukodystrophy and Adult Onset Leukoencephalopathy With Axonal Spheroids and Pigmented Glia
Withdrawn NCT01787578 - Safety and Pharmacodynamic Study of Sobetirome in X-Linked Adrenoleukodystrophy (X-ALD) Phase 1